Cargando…

Negotiating prices of drugs for rare diseases

Detalles Bibliográficos
Autores principales:	Henrard, Séverine, Arickx, Francis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Health Organization 2016
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043200/ https://www.ncbi.nlm.nih.gov/pubmed/27843170 http://dx.doi.org/10.2471/BLT.15.163519

Ejemplares similares

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
por: Rawson, Nigel S. B.
Publicado: (2022)

Payer-Negotiated Prices for Telemedicine Services
por: Wu, Shannon S., et al.
Publicado: (2022)

Success, failure, and the imperative for justice in climate negotiations
por: Laybourn-Langton, Laurie
Publicado: (2023)

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022)

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022)

Comparison of US Hospital Cash Prices and Commercial Negotiated Prices for 70 Services
por: Jiang, John (Xuefeng), et al.
Publicado: (2021)

Smith’s paradox of price and negotiation: Empirical evidence from India
por: Dey Biswas, Sattwick
Publicado: (2021)

When names are on the line: Negotiating authorship with your team
por: Regehr, Glenn
Publicado: (2021)

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
por: Franzen, Nora, et al.
Publicado: (2022)

Pricing of orphan drugs in oncology and rare diseases
por: Nuijten, Mark, et al.
Publicado: (2020)

Drugs Against Rare Diseases: Are The Regulatory Standards Higher?
por: Gobburu, J, et al.
Publicado: (2016)

The economics of moonshots: Value in rare disease drug development
por: Yates, Nathan, et al.
Publicado: (2022)

Medicines Prices and Malaysia—Untangling the Medicines Web
por: Hill, Suzanne
Publicado: (2007)

Environmental Justice and Carbon Pricing: Can They Be Reconciled?
por: Boyce, James K., et al.
Publicado: (2023)

Fee-for-value in the pharmaceutical industry: a policy framework applying data science to negotiate drug prices
por: Patel, Nisarg A.
Publicado: (2017)

Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China
por: Mingge, Xia, et al.
Publicado: (2023)

The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China
por: Bao, Yuwen, et al.
Publicado: (2023)

Negotiating with Backbone: Eight Sales Strategies to Defend Your Price and Value
por: Holden, Reed
Publicado: (2012)

Negotiating with Backbone: Eight Sales Strategies to Defend Your Price and Value
por: Holden, Reed
Publicado: (2015)

"Sell an Ox" - The Price of Cure for Hepatitis C in Two Countries
por: Paltiel, Ora, et al.
Publicado: (2019)

Using strategic price negotiations to contain costs and expand access to medicines in China
por: Si, Lei, et al.
Publicado: (2020)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
por: Wu, Di, et al.
Publicado: (2022)

Factors Associated With Hospital Commercial Negotiated Price for Magnetic Resonance Imaging of Brain
por: Jiang, John Xuefeng, et al.
Publicado: (2023)

Carbon pricing, co-pollutants, and climate policy: Evidence from California
por: Boyce, James K., et al.
Publicado: (2018)

Impacts of National Drug Price Negotiation on Expenditure, Volume, and Availability of Targeted Anti-Cancer Drugs in China: An Interrupted Time Series Analysis
por: Sun, Yan, et al.
Publicado: (2022)

The price they paid
por: York, Eugene P., et al.
Publicado: (2015)

Comparison of Commercial Negotiated Price and Cash Price Between Physician-Owned Hospitals and Other Hospitals in the Same Hospital Referral Region
por: Wang, Yang, et al.
Publicado: (2023)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

Sky-High Air Ambulance Prices
por: Kelly, Maura
Publicado: (2020)

Institutions for health care price setting and regulation: A comparative review of eight settings
por: Barber, Sarah L., et al.
Publicado: (2019)

Estimating the number of diseases – the concept of rare, ultra-rare, and hyper-rare
por: Smith, C. I. Edvard, et al.
Publicado: (2022)

Rare Mutations in Cancer Drug Resistance and Implications for Therapy
por: Beckman, Robert A., et al.
Publicado: (2020)

Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations
por: Jaksa, Ashley, et al.
Publicado: (2023)

The Price of Inequality in Type 1 Diabetes Management
por: Herringshaw, Emilee
Publicado: (2022)

Making Every Subject Count: A Case Study of Drug Development Path for Medication in a Pediatric Rare Disease
por: Bhattacharya, I, et al.
Publicado: (2016)

A Rare Lymphoproliferative Disease: Castleman Disease
por: Gündüz, Eren, et al.
Publicado: (2021)

Promoting Less Complex and More Honest Price Negotiations in the Online Used Car Market with Authenticated Data
por: Engelmann, Andreas, et al.
Publicado: (2022)

Invited Perspective: Vibriosis—The Price Tag of a Warmer World
por: Semenza, Jan C.
Publicado: (2022)

Managing high-priced biologic agents: challenges and potential solutions
por: Li, Meng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pgnebqsotnaa2vps0qds64c3v0